The presidency of Barack Obama seeks a major transformation of American politics and policy. This new collection, edited by Steven E. Schier, examines the unusual combination of risk and ambition in Obama's presidency concerning popular politics, Washington politics, and economic and foreign policy. It also places the Obama presidency in historical perspective, noting the unusual circumstances of his election and the similarities and differences between presidential politics today and those of previous eras. Transforming America: Barack Obama in the White House provides a guiding focus involving the successes and failures of the administration's transformative aspirations during Obama's initial years in the White House. Contributions by John J. Coleman, James L. Guth, John F. Harris, James Hohmann, Bertram Johnson, Richard E. Matland, Nancy Maveety, James M. McCormick, John J. Pitney Jr, Nicol C. Rae, Steven E. Schier, Raymond Tatalovich, Andrea L. Walker, and John K. White.

Prescription Drug Diversion and Pain provides an interdisciplinary overview of medications used to treat chronic pain, specifically the benefits and risks that are posed by long-term opioids use. These essential pain-relieving medications must be carefully managed to prevent serious side effects that may include physical dependence, addiction, and even death, which has led in recent years to increased attention on the development of alternative treatments for chronic pain. This book not only offers a single, comprehensive source for understanding the specialized field of the opioid crisis, but also addresses provocative topics including how pain drugs came to be regulated by the U.S. Government and the rarely-discussed aggressive marketing behind the spread of these drugs. Chapters are written by expert contributors from diverse backgrounds in medicine, psychiatry, pharmacy, nursing, health law, and ethics. Prescription Drug Diversion and Pain is a must-read for healthcare professionals, caregivers, policy makers, regulatory officials, law enforcement, and those in the pharmaceutical industry seeking to address the current and future opioid crisis.